Innoviva (INVA) Total Non-Current Liabilities (2013 - 2026)
Innoviva (INVA) posted Total Non-Current Liabilities of -$68.9 million for Q1 2026, down 21.28% on a QoQ basis from -$56.8 million in Q4 2025, and down 494.3% year-over-year from $17.5 million in Q1 2025.
Innoviva (INVA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Innoviva's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at -$68.9 million for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 494.3% year-over-year to -$68.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.9 million (down 494.3% YoY) and the FY2025 annual result came in at -$56.8 million, up 11.33% from the prior year.
- Total Non-Current Liabilities was -$68.9 million for Q1 2026 at Innoviva, down from -$56.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $103.3 million in Q3 2023 and bottomed at -$71.5 million in Q2 2024.
- A 5-year average of -$11.1 million and a median of -$55.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 20050.0% — and 2026, when it plunged 494.3%.
- Innoviva's Total Non-Current Liabilities stood at $40.3 million in 2022, then soared by 156.24% to $103.3 million in 2023, then sank by 162.05% to -$64.1 million in 2024, then grew by 11.33% to -$56.8 million in 2025, then fell by 21.28% to -$68.9 million in 2026.
- Business Quant data shows INVA's Total Non-Current Liabilities at -$68.9 million in Q1 2026, -$56.8 million in Q4 2025, and $45.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | -68.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.90 Mn |
| Dec 31, 2025 | -56.81 Mn |
| Sep 30, 2025 | 45.15 Mn |
| Jun 30, 2025 | -55.05 Mn |
| Mar 31, 2025 | -11.59 Mn |
| Dec 31, 2024 | -64.08 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Jun 30, 2024 | -71.47 Mn |
| Mar 31, 2024 | -68.26 Mn |
| Dec 31, 2023 | 103.26 Mn |
| Sep 30, 2023 | 103.26 Mn |
| Jun 30, 2023 | -67.88 Mn |
| Mar 31, 2023 | -66.03 Mn |
| Dec 31, 2022 | 40.30 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 13.66 Mn |
| Jun 30, 2021 | 789.11 Mn |
| Mar 31, 2021 | 1.09 Bn |
| Dec 31, 2020 | 999.46 Mn |